To our knowledge, this is the first randomized clinical trial demonstrating an isotoxic improvement in prostate cancer control outcomes with intensification of SRT informed by PSMA-PET in men who present with BCR after RP, in a modern cohort with prevalent use of adjuvant HT. This evidence concerns the gene FOLH1 and Familial prostate cancer.